Predisposing factors for critical illness polyneuromyopathy in a multidisciplinary intensive care unit

Objective –  To investigate risk factors of critical illness polyneuromyopathy (CIPM) in a general multidisciplinary intensive care unit (ICU). Patients and methods –  Prospective observational study in a 28‐bed university multidisciplinary ICU. Four hundred and seventy‐four (323 M/151 F, age 55 ± 1...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Acta neurologica Scandinavica 2008-09, Vol.118 (3), p.175-181
Hauptverfasser: Nanas, S., Kritikos, K., Angelopoulos, E., Siafaka, A., Tsikriki, S., Poriazi, M., Kanaloupiti, D., Kontogeorgi, M., Pratikaki, M., Zervakis, D., Routsi, C., Roussos, C.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 181
container_issue 3
container_start_page 175
container_title Acta neurologica Scandinavica
container_volume 118
creator Nanas, S.
Kritikos, K.
Angelopoulos, E.
Siafaka, A.
Tsikriki, S.
Poriazi, M.
Kanaloupiti, D.
Kontogeorgi, M.
Pratikaki, M.
Zervakis, D.
Routsi, C.
Roussos, C.
description Objective –  To investigate risk factors of critical illness polyneuromyopathy (CIPM) in a general multidisciplinary intensive care unit (ICU). Patients and methods –  Prospective observational study in a 28‐bed university multidisciplinary ICU. Four hundred and seventy‐four (323 M/151 F, age 55 ± 19) consecutive patients were prospectively evaluated. All patients were assigned admission Acute Physiology and Chronic Health Evaluation (APACHE II; 15 ± 7) and Sequential Organ Failure Assessment (SOFA; 6 ± 3) scores and were subsequently evaluated for newly developed neuromuscular weakness. Other potential causes of new‐onset weakness after ICU admission were excluded before CIPM was diagnosed. Results –  Forty‐four (23.8%) of 185 patients developed generalized weakness that met the criteria for CIPM. Patients with CIPM had higher APACHE II (18.9 ± 6.6 vs 15.6 ± 6.4, P = 0.004) and SOFA scores (8.4 ± 2.9 vs 7.1 ± 2.9, P = 0.013). According to multivariate logistic regression analysis, the following risk factors were independently associated with the development of CIPM: severity of illness at the time of ICU admission, administration of aminoglycoside antibiotics and high blood glucose levels. Analysis according to severity of illness stratification revealed the emergence of Gram (−) bacteremia as the most important independent predisposing factor for CIPM development in less severely ill patients. Conclusions –  CIPM has a high incidence in the ICU setting. Our study revealed the association of aminoglycosides, hyperglycemia and illness severity with CIPM development, as well as the association between Gram (−) bacteremia and development of CIPM in less severely ill patient population.
doi_str_mv 10.1111/j.1600-0404.2008.00996.x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_21026935</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>21026935</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5816-b89f5f825234f2d3197f4e5f7c9688383dc3f5af25c3971d2b005e904f331d23</originalsourceid><addsrcrecordid>eNqNkF2P1CAUhonRuOPqXzDc6F0rH6WFxJt1s7uaTMaPbLKXhKGgjBQqtOvMv5c6k_FWbuDA8x5OHgAgRjUu692uxi1CFWpQUxOEeI2QEG29fwJW54enYIUQwlVLcXMBXuS8KxXpmuY5uMCcMkYFWwH7JZne5TFmF75Dq_QUU4Y2JqiTm5xWHjrvg8kZjtEfgplTHA5xVNOPA3QBKjjMfnKlhXajd0Gl5XoyIbtHA7VKBs7BTS_BM6t8Nq9O-yW4v725v_5YrT_ffbq-WleacdxWWy4ss5wwQhtLeopFZxvDbKdFyznltNfUMmUJ01R0uCdbhJgRqLGUlopegrfHtmOKv2aTJzmUwYz3Kpg4Z0kwIq2grID8COoUc07GyjG5oQwvMZKLYrmTi0m5mJSLYvlXsdyX6OvTH_N2MP2_4MlpAd6cAJWLP5tU0C6fOYJYxzGlhXt_5H47bw7_PYC82tyUQ4lXx7jLk9mf4yr9lG1HOyYfNnfya_thvXn4tpG39A8slKfh</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>21026935</pqid></control><display><type>article</type><title>Predisposing factors for critical illness polyneuromyopathy in a multidisciplinary intensive care unit</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Nanas, S. ; Kritikos, K. ; Angelopoulos, E. ; Siafaka, A. ; Tsikriki, S. ; Poriazi, M. ; Kanaloupiti, D. ; Kontogeorgi, M. ; Pratikaki, M. ; Zervakis, D. ; Routsi, C. ; Roussos, C.</creator><creatorcontrib>Nanas, S. ; Kritikos, K. ; Angelopoulos, E. ; Siafaka, A. ; Tsikriki, S. ; Poriazi, M. ; Kanaloupiti, D. ; Kontogeorgi, M. ; Pratikaki, M. ; Zervakis, D. ; Routsi, C. ; Roussos, C.</creatorcontrib><description>Objective –  To investigate risk factors of critical illness polyneuromyopathy (CIPM) in a general multidisciplinary intensive care unit (ICU). Patients and methods –  Prospective observational study in a 28‐bed university multidisciplinary ICU. Four hundred and seventy‐four (323 M/151 F, age 55 ± 19) consecutive patients were prospectively evaluated. All patients were assigned admission Acute Physiology and Chronic Health Evaluation (APACHE II; 15 ± 7) and Sequential Organ Failure Assessment (SOFA; 6 ± 3) scores and were subsequently evaluated for newly developed neuromuscular weakness. Other potential causes of new‐onset weakness after ICU admission were excluded before CIPM was diagnosed. Results –  Forty‐four (23.8%) of 185 patients developed generalized weakness that met the criteria for CIPM. Patients with CIPM had higher APACHE II (18.9 ± 6.6 vs 15.6 ± 6.4, P = 0.004) and SOFA scores (8.4 ± 2.9 vs 7.1 ± 2.9, P = 0.013). According to multivariate logistic regression analysis, the following risk factors were independently associated with the development of CIPM: severity of illness at the time of ICU admission, administration of aminoglycoside antibiotics and high blood glucose levels. Analysis according to severity of illness stratification revealed the emergence of Gram (−) bacteremia as the most important independent predisposing factor for CIPM development in less severely ill patients. Conclusions –  CIPM has a high incidence in the ICU setting. Our study revealed the association of aminoglycosides, hyperglycemia and illness severity with CIPM development, as well as the association between Gram (−) bacteremia and development of CIPM in less severely ill patient population.</description><identifier>ISSN: 0001-6314</identifier><identifier>EISSN: 1600-0404</identifier><identifier>DOI: 10.1111/j.1600-0404.2008.00996.x</identifier><identifier>PMID: 18355395</identifier><identifier>CODEN: ANRSAS</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Aminoglycosides - adverse effects ; Anti-Bacterial Agents - adverse effects ; APACHE ; Bacteremia - complications ; Biological and medical sciences ; Blood Glucose ; critical illness polyneuromyopathy ; Female ; Gram (−) bacteremia ; Gram-Negative Bacterial Infections - complications ; Humans ; hyperglycemia ; Hyperglycemia - complications ; hypoalbuminemia ; incidence ; Intensive Care Units - statistics &amp; numerical data ; Male ; Medical sciences ; Middle Aged ; Neurology ; Polyneuropathies - epidemiology ; Polyneuropathies - etiology ; Polyneuropathies - physiopathology ; Risk Factors ; Vascular diseases and vascular malformations of the nervous system</subject><ispartof>Acta neurologica Scandinavica, 2008-09, Vol.118 (3), p.175-181</ispartof><rights>Copyright © 2008 The Authors. Journal compilation © 2008 Blackwell Munksgaard</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5816-b89f5f825234f2d3197f4e5f7c9688383dc3f5af25c3971d2b005e904f331d23</citedby><cites>FETCH-LOGICAL-c5816-b89f5f825234f2d3197f4e5f7c9688383dc3f5af25c3971d2b005e904f331d23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1600-0404.2008.00996.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1600-0404.2008.00996.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=20578133$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18355395$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nanas, S.</creatorcontrib><creatorcontrib>Kritikos, K.</creatorcontrib><creatorcontrib>Angelopoulos, E.</creatorcontrib><creatorcontrib>Siafaka, A.</creatorcontrib><creatorcontrib>Tsikriki, S.</creatorcontrib><creatorcontrib>Poriazi, M.</creatorcontrib><creatorcontrib>Kanaloupiti, D.</creatorcontrib><creatorcontrib>Kontogeorgi, M.</creatorcontrib><creatorcontrib>Pratikaki, M.</creatorcontrib><creatorcontrib>Zervakis, D.</creatorcontrib><creatorcontrib>Routsi, C.</creatorcontrib><creatorcontrib>Roussos, C.</creatorcontrib><title>Predisposing factors for critical illness polyneuromyopathy in a multidisciplinary intensive care unit</title><title>Acta neurologica Scandinavica</title><addtitle>Acta Neurol Scand</addtitle><description>Objective –  To investigate risk factors of critical illness polyneuromyopathy (CIPM) in a general multidisciplinary intensive care unit (ICU). Patients and methods –  Prospective observational study in a 28‐bed university multidisciplinary ICU. Four hundred and seventy‐four (323 M/151 F, age 55 ± 19) consecutive patients were prospectively evaluated. All patients were assigned admission Acute Physiology and Chronic Health Evaluation (APACHE II; 15 ± 7) and Sequential Organ Failure Assessment (SOFA; 6 ± 3) scores and were subsequently evaluated for newly developed neuromuscular weakness. Other potential causes of new‐onset weakness after ICU admission were excluded before CIPM was diagnosed. Results –  Forty‐four (23.8%) of 185 patients developed generalized weakness that met the criteria for CIPM. Patients with CIPM had higher APACHE II (18.9 ± 6.6 vs 15.6 ± 6.4, P = 0.004) and SOFA scores (8.4 ± 2.9 vs 7.1 ± 2.9, P = 0.013). According to multivariate logistic regression analysis, the following risk factors were independently associated with the development of CIPM: severity of illness at the time of ICU admission, administration of aminoglycoside antibiotics and high blood glucose levels. Analysis according to severity of illness stratification revealed the emergence of Gram (−) bacteremia as the most important independent predisposing factor for CIPM development in less severely ill patients. Conclusions –  CIPM has a high incidence in the ICU setting. Our study revealed the association of aminoglycosides, hyperglycemia and illness severity with CIPM development, as well as the association between Gram (−) bacteremia and development of CIPM in less severely ill patient population.</description><subject>Aminoglycosides - adverse effects</subject><subject>Anti-Bacterial Agents - adverse effects</subject><subject>APACHE</subject><subject>Bacteremia - complications</subject><subject>Biological and medical sciences</subject><subject>Blood Glucose</subject><subject>critical illness polyneuromyopathy</subject><subject>Female</subject><subject>Gram (−) bacteremia</subject><subject>Gram-Negative Bacterial Infections - complications</subject><subject>Humans</subject><subject>hyperglycemia</subject><subject>Hyperglycemia - complications</subject><subject>hypoalbuminemia</subject><subject>incidence</subject><subject>Intensive Care Units - statistics &amp; numerical data</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neurology</subject><subject>Polyneuropathies - epidemiology</subject><subject>Polyneuropathies - etiology</subject><subject>Polyneuropathies - physiopathology</subject><subject>Risk Factors</subject><subject>Vascular diseases and vascular malformations of the nervous system</subject><issn>0001-6314</issn><issn>1600-0404</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkF2P1CAUhonRuOPqXzDc6F0rH6WFxJt1s7uaTMaPbLKXhKGgjBQqtOvMv5c6k_FWbuDA8x5OHgAgRjUu692uxi1CFWpQUxOEeI2QEG29fwJW54enYIUQwlVLcXMBXuS8KxXpmuY5uMCcMkYFWwH7JZne5TFmF75Dq_QUU4Y2JqiTm5xWHjrvg8kZjtEfgplTHA5xVNOPA3QBKjjMfnKlhXajd0Gl5XoyIbtHA7VKBs7BTS_BM6t8Nq9O-yW4v725v_5YrT_ffbq-WleacdxWWy4ss5wwQhtLeopFZxvDbKdFyznltNfUMmUJ01R0uCdbhJgRqLGUlopegrfHtmOKv2aTJzmUwYz3Kpg4Z0kwIq2grID8COoUc07GyjG5oQwvMZKLYrmTi0m5mJSLYvlXsdyX6OvTH_N2MP2_4MlpAd6cAJWLP5tU0C6fOYJYxzGlhXt_5H47bw7_PYC82tyUQ4lXx7jLk9mf4yr9lG1HOyYfNnfya_thvXn4tpG39A8slKfh</recordid><startdate>200809</startdate><enddate>200809</enddate><creator>Nanas, S.</creator><creator>Kritikos, K.</creator><creator>Angelopoulos, E.</creator><creator>Siafaka, A.</creator><creator>Tsikriki, S.</creator><creator>Poriazi, M.</creator><creator>Kanaloupiti, D.</creator><creator>Kontogeorgi, M.</creator><creator>Pratikaki, M.</creator><creator>Zervakis, D.</creator><creator>Routsi, C.</creator><creator>Roussos, C.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope></search><sort><creationdate>200809</creationdate><title>Predisposing factors for critical illness polyneuromyopathy in a multidisciplinary intensive care unit</title><author>Nanas, S. ; Kritikos, K. ; Angelopoulos, E. ; Siafaka, A. ; Tsikriki, S. ; Poriazi, M. ; Kanaloupiti, D. ; Kontogeorgi, M. ; Pratikaki, M. ; Zervakis, D. ; Routsi, C. ; Roussos, C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5816-b89f5f825234f2d3197f4e5f7c9688383dc3f5af25c3971d2b005e904f331d23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Aminoglycosides - adverse effects</topic><topic>Anti-Bacterial Agents - adverse effects</topic><topic>APACHE</topic><topic>Bacteremia - complications</topic><topic>Biological and medical sciences</topic><topic>Blood Glucose</topic><topic>critical illness polyneuromyopathy</topic><topic>Female</topic><topic>Gram (−) bacteremia</topic><topic>Gram-Negative Bacterial Infections - complications</topic><topic>Humans</topic><topic>hyperglycemia</topic><topic>Hyperglycemia - complications</topic><topic>hypoalbuminemia</topic><topic>incidence</topic><topic>Intensive Care Units - statistics &amp; numerical data</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neurology</topic><topic>Polyneuropathies - epidemiology</topic><topic>Polyneuropathies - etiology</topic><topic>Polyneuropathies - physiopathology</topic><topic>Risk Factors</topic><topic>Vascular diseases and vascular malformations of the nervous system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nanas, S.</creatorcontrib><creatorcontrib>Kritikos, K.</creatorcontrib><creatorcontrib>Angelopoulos, E.</creatorcontrib><creatorcontrib>Siafaka, A.</creatorcontrib><creatorcontrib>Tsikriki, S.</creatorcontrib><creatorcontrib>Poriazi, M.</creatorcontrib><creatorcontrib>Kanaloupiti, D.</creatorcontrib><creatorcontrib>Kontogeorgi, M.</creatorcontrib><creatorcontrib>Pratikaki, M.</creatorcontrib><creatorcontrib>Zervakis, D.</creatorcontrib><creatorcontrib>Routsi, C.</creatorcontrib><creatorcontrib>Roussos, C.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>Acta neurologica Scandinavica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nanas, S.</au><au>Kritikos, K.</au><au>Angelopoulos, E.</au><au>Siafaka, A.</au><au>Tsikriki, S.</au><au>Poriazi, M.</au><au>Kanaloupiti, D.</au><au>Kontogeorgi, M.</au><au>Pratikaki, M.</au><au>Zervakis, D.</au><au>Routsi, C.</au><au>Roussos, C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predisposing factors for critical illness polyneuromyopathy in a multidisciplinary intensive care unit</atitle><jtitle>Acta neurologica Scandinavica</jtitle><addtitle>Acta Neurol Scand</addtitle><date>2008-09</date><risdate>2008</risdate><volume>118</volume><issue>3</issue><spage>175</spage><epage>181</epage><pages>175-181</pages><issn>0001-6314</issn><eissn>1600-0404</eissn><coden>ANRSAS</coden><abstract>Objective –  To investigate risk factors of critical illness polyneuromyopathy (CIPM) in a general multidisciplinary intensive care unit (ICU). Patients and methods –  Prospective observational study in a 28‐bed university multidisciplinary ICU. Four hundred and seventy‐four (323 M/151 F, age 55 ± 19) consecutive patients were prospectively evaluated. All patients were assigned admission Acute Physiology and Chronic Health Evaluation (APACHE II; 15 ± 7) and Sequential Organ Failure Assessment (SOFA; 6 ± 3) scores and were subsequently evaluated for newly developed neuromuscular weakness. Other potential causes of new‐onset weakness after ICU admission were excluded before CIPM was diagnosed. Results –  Forty‐four (23.8%) of 185 patients developed generalized weakness that met the criteria for CIPM. Patients with CIPM had higher APACHE II (18.9 ± 6.6 vs 15.6 ± 6.4, P = 0.004) and SOFA scores (8.4 ± 2.9 vs 7.1 ± 2.9, P = 0.013). According to multivariate logistic regression analysis, the following risk factors were independently associated with the development of CIPM: severity of illness at the time of ICU admission, administration of aminoglycoside antibiotics and high blood glucose levels. Analysis according to severity of illness stratification revealed the emergence of Gram (−) bacteremia as the most important independent predisposing factor for CIPM development in less severely ill patients. Conclusions –  CIPM has a high incidence in the ICU setting. Our study revealed the association of aminoglycosides, hyperglycemia and illness severity with CIPM development, as well as the association between Gram (−) bacteremia and development of CIPM in less severely ill patient population.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>18355395</pmid><doi>10.1111/j.1600-0404.2008.00996.x</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0001-6314
ispartof Acta neurologica Scandinavica, 2008-09, Vol.118 (3), p.175-181
issn 0001-6314
1600-0404
language eng
recordid cdi_proquest_miscellaneous_21026935
source MEDLINE; Wiley Online Library All Journals
subjects Aminoglycosides - adverse effects
Anti-Bacterial Agents - adverse effects
APACHE
Bacteremia - complications
Biological and medical sciences
Blood Glucose
critical illness polyneuromyopathy
Female
Gram (−) bacteremia
Gram-Negative Bacterial Infections - complications
Humans
hyperglycemia
Hyperglycemia - complications
hypoalbuminemia
incidence
Intensive Care Units - statistics & numerical data
Male
Medical sciences
Middle Aged
Neurology
Polyneuropathies - epidemiology
Polyneuropathies - etiology
Polyneuropathies - physiopathology
Risk Factors
Vascular diseases and vascular malformations of the nervous system
title Predisposing factors for critical illness polyneuromyopathy in a multidisciplinary intensive care unit
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T09%3A03%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predisposing%20factors%20for%20critical%20illness%20polyneuromyopathy%20in%20a%20multidisciplinary%20intensive%20care%20unit&rft.jtitle=Acta%20neurologica%20Scandinavica&rft.au=Nanas,%20S.&rft.date=2008-09&rft.volume=118&rft.issue=3&rft.spage=175&rft.epage=181&rft.pages=175-181&rft.issn=0001-6314&rft.eissn=1600-0404&rft.coden=ANRSAS&rft_id=info:doi/10.1111/j.1600-0404.2008.00996.x&rft_dat=%3Cproquest_cross%3E21026935%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=21026935&rft_id=info:pmid/18355395&rfr_iscdi=true